Skip to main content

Eli Lilly and Company guidance

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.37T

In its results release of 29 Oct 2026 (Q3 FY2026), Eli Lilly and Company gave 3 forecasts in figures, among them revenue of $91.00B to $92.00B for FY2026. Over the last two years, results landed above the company's own last range 2 of 6 times, within it 1 and below it 3.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
RevenueFY2026$91.00B to $92.00BRevenue $91 to $92 billion
EPSFY2026$35.00 to $36.00Earnings per Share $35.00 to $36.00
Tax rateFY202619% to 20%Tax Rate 19% to 20%

Source: the company's earnings release.

Guidance against results above 2 · within 1 · below 3

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$91.00B to $92.00BRaised 3 times—To come
EPS · AdjustedFY2026$35.50 to $37.00Raised once—To come
EPSFY2026$35.00 to $36.00Lowered once—To come
Tax rateFY202619% to 20%Raised once—To come
RevenueFY2025$63.00B to $63.50BRaised twice$65.18BAbove the range
Revenue growthFY2025+32%Given once+44.7%Above the range
EPS · GAAPFY2025$22.05 to $23.55Given once$22.95Within the range
Tax rateFY202519%Raised twice19.79%Above the range
RevenueFY2024$45.40B to $46.00BGiven once$45.04BBelow the range
EPS · GAAPFY2024$12.05 to $12.55Given once$11.71Below the range
Tax rateFY202417%Given once16.48%Below the range

LLY in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.